Striking New Forest home, in three acres with home cinema, for sale for £2.395m
Aldermoor Lodge in Ipley, Marchwood is a design triumph which boasts impressive reception rooms and a main bedroom with dressing room and ensuite, plus four other large bedrooms.
Off of the bright and spacious entrance hall, there's a stunning wood and glass crafted staircase rising to a partially galleried landing.
(Image: Savills)READ MORE: £4m former mill with fishing and 22 acres for sale for first time in decades
Pocket sliding doors allow for versatile use of the living spaces throughout. Underfloor heating runs beneath stylish stone tiles in the principal living areas and bathrooms, while plush carpets add warmth and comfort to all bedrooms.
From the main hallway, there's access to the cloakroom, ground-floor bedroom suite, study, open-plan kitchen and dining area, utility/laundry room, living room and snug.
Upstairs, the part-galleried landing leads to four large bedrooms, both the principal and guest suites benefiting from vaulted ceilings, dedicated dressing areas with fitted wardrobes, en suite bathrooms and balconies.
(Image: Savills) Approached via a forest track and accessed through remote controlled wooden gates, the property is set within 3.4 acres of exceptional gardens and grounds with wild meadows, a detached triple garage building, a studio / garden room and pond.
Strolls through the surrounding forest lead to scenic spots along the upper reaches of the Beaulieu River.
Giles Muddle, of agents Savills, said: "Aldermoor Lodge is a very special contemporary home in a prime New Forest location within glorious habitat and with an abundance of wildlife."
(Image: Savills) The river flows along the eastern boundary of the grounds, which boast open access to the New Forest.
Dibden Purlieu and Hythe are both less than three miles away, while Southampton is only seven and a half miles from the property.
The nearby A326 connects to the M27 motorway, providing links along the South Coast and to the M3 towards London. For travel beyond, Southampton and Poole Channel ports, Southampton International Airport, and mainline railway stations at Beaulieu Road, Brockenhurst, and Southampton offer regular services to London Waterloo.
(Image: Savills)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscape Designed to address emerging areas of patient need, including long-term weight management, co-morbid metabolic disorders, and muscle preservation during weight loss Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. ('Nxera'; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders. Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline across a broad range of validated GPCR targets in these major disorders. Chris Cargill, President and CEO of Nxera, commented: 'Nxera scientists were among the pioneers in elucidating the structure of the GLP-1 receptor and other key receptors being targeted, giving us a clear advantage in developing potentially best-in-class next generation drug candidates. For the past 12 months, Nxera scientists have been advancing a broad metabolic disease pipeline to capitalize independently on our differentiated science. Today, we reveal the addition of these programs to our discovery portfolio, and are confident in achieving significant progress over the mid-term, delivering clear value for shareholders and patients in the rapidly expanding obesity market, projected to exceed US$100 billion annually in global sales.' Central to Nxera's pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from Pfizer's PF-06954522, allowing Nxera full control to drive rapid progress. Complementing this program, Nxera is simultaneously accelerating the advancement of an additional six established GPCR-targeted programs focused on obesity and chronic weight management: Three small molecule agonist programs (GIP, Apelin, Amylin) One small molecule antagonist program (GIP) Two long-acting programs (targets undisclosed) Nxera's pipeline leverages its proprietary NxWave™ GPCR-focused structure-based design platform to rapidly identify unique, highly differentiated lead molecules with novel chemistry. This process utilizes Nxera's NxHit proprietary small molecule libraries and NxStaR proteins for DNA encoded library (DEL) screening, distinguishing these candidates from others currently in discovery and clinical development globally. Nxera's focused approach is designed to deliver highly effective therapies addressing critical patient needs: Long-term weight maintenance: Convenient, scalable oral therapies for sustained weight loss. Targeting key obesity-related co-morbidities: Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously. Reducing side effects and broadening out to difficult to treat populations: Targeted treatments for elderly, post-menopausal, and sarcopenic populations. Backed by an expert team with deep experience in GPCR drug discovery, Nxera is strategically positioned to be a leader in developing the next generation of best-in-class obesity and metabolic therapies. Nxera maintains its strong commitment to other key therapeutic areas including neurology, gastroenterology, and immunology, continuing to leverage the NxWave™ platform's proven capabilities in these domains. Separately, Nxera notes that Pfizer yesterday discontinued development of its Phase 1 candidate PF-06954522, a separate small molecule GLP-1 agonist, which was discovered under a strategic drug discovery collaboration with Nxera. This discontinuation by Pfizer was due to a portfolio decision and not because of any adverse safety findings. Nxera intends to enter discussions with Pfizer regarding potential opportunities to advance GLP-1 molecules discovered by Pfizer under the collaboration. Nxera will announce its earnings results and present operational highlights for Q2 2025 on Friday, 8 August 2025. –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@ MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@ Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or in to access your portfolio
Wall Street Journal
8 minutes ago
- Wall Street Journal
U.K. Government Likely to Lean on Tax Rises to Avoid Budget Rules Breach, NIESR Says
The U.K. government is set to break its fiscal rules unless it raises taxes or cuts spending when it unveils its new budget plans later this year, the U.K.'s National Institute of Economic and Social Research said Wednesday. In a quarterly report, the U.K.'s leading economic research body also said inflation is likely to remain stubbornly high this year, but expects the Bank of England to lower borrowing costs Thursday and once more before the end of the year.
Forbes
8 minutes ago
- Forbes
There's An Under-The-Radar Rothy's Sale Happening Right Now
When I first heard of Rothy's years ago, I was immediately intrigued by its sustainable, machine-washable styles. Since then, the brand has only grown in popularity, becoming a reliable choice for commuters, frequent travelers and anyone seeking durable, low-maintenance footwear. Our editors (myself included) swear by several of the its designs, thanks to their non-existent break-in period, all-day comfort and breathable materials. If you've yet to try the brand out, there's an unofficialy Rothy's sale happening right now, and several of our favorite pairs including The Buckle Slide and The Square Mary Jane are up to 48% off. There's an under-the-radar Rothy's sale happening right now. Shop editor-loved pairs for up to 48% ... More off. ILLUSTRATION: FORBES / PHOTOS: RETAILER Rothy's Final Few sale section features highly rated styles in select colorways—like The Loafer and The Point—at varying reduced prices. These discounted pairs are on their way out for good (each purchase is final sale), making it the perfect opportunity to try out some of the brand's beloved designs without paying full price. Up ahead, find out which Rothy's shoes our editors own and love, alongside other standout styles that are available until stock runs out. I picked up this pair of buckle slides back in early spring, and have worn them on multiple occasions since—to the pool, to rooftop happy hour and while running errands around my neighborhood. They look way sleeker than most slide sandals I've owned, but they're extremely comfortable. I noticed the cushioned support from the firm, contoured footbed the very first time I slipped them on. Plus, the straps don't ever dig into my skin. I can walk in these for hours and not feel the slightest bit of pain at the end of the day. They are currently discounted in black (my chosen color), alongside two other neutral shade options. At the beginning of the summer, our special projects editor Jennifer Ferrise was looking for a block heel sandal that she could wear around New York City without getting blisters. She landed on this pair from Rothy's—her very first purchase from the brand—and was pleasantly surprised by how comfortable and lightweight they were. 'They have a plush, cushioned footbed and have never hurt my feet, even after walking around all day. I love that they look polished enough for both the daytime and evening, and that you can also toss them in the washer for a quick and easy clean,' she says. Senior updates editor Karen Tietjen has owned this loafer from Rothy's for quite some time, and still wears them to this day. "I have a wider foot and can attest that these are comfy (and work way better for my foot shape than The Point flats, as much as it pains me to admit). As someone who refuses to wear casual sneakers without socks, these are a lightweight, breathable closed-toe option that's great for that in-between weather around spring and fall." They're currently discounted in the pictured Ecru colorway. Deputy editor Jane Sung loves wearing these Rothy's flats to round out a polished outfit. 'I wear them everywhere—running errands, traveling and to dinners out. They're just so comfortable. Between the woven material and rounded square toe shape, they're a sophisticated take on classic Mary Janes,' she says. They've also quickly become one of commerce editor Katherine Louie's most-worn pairs of shoes, since the fabric is flexible and breathable. 'I was able to wear them right out of the box without experiencing any uncomfortable rubbing or blisters," she says. "I've washed these flats several times (living in New York City is hard on shoes!) and they retain their shape well and still look brand new.' If you've still got some summer travel plans on the docket, this slip-on sandal may be worth packing in your suitcase. It features comfortable and supportive insoles that won't cause blisters, no matter how many steps you're tracking in a day. In addition, its flexible upper offers a secure fit while the EVA outsole ensures you won't feel weighed down. If they get a little dirty on your adventures, just toss them in the wash and air-dry for a like-new look. All five colors, including the pictured colorway, are currently discounted. Rothy's also makes comfortable everyday sneakers. Like most of the brand's designs, this pair includes supportive features to keep your feet free from pain, like a contoured footbed, adjustable laces, sturdy outsoles and a padded ankle collar with proper cushioning. The sneaker is also available in women's sizes for as little as $59 right now. Like many compact Rothy's styles, this ballet flat can easily be thrown into your bag for when you need a quick shoe change. It features a rounded toe box, heel-to-toe cushioning and sculpted outsoles for superior comfort, whether you're heading to and from the office or running to post-work activities. Three color options are all sale for $99, including the bold red shade shown above. Loafers are a great transitional shoe to take you from summer to autumn. This style from Rothy's has solid grip and durability and a plush footbed for a shoe that's lightweight, springy and stable across a variety of surfaces. Several colorways are included in the sale, but the discounts vary depending on color selection.
